- Home
- APXT vs ABEO Comparison
APXT vs ABEO Comparison
Compare APXT & ABEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | APXT | ABEO |
|---|---|---|
| Founded | 2025 | 1974 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 461.0M | 399.5M |
| IPO Year | 2025 | 2005 |
Fundamental Metrics
Financial Performance| Metric | APXT | ABEO |
|---|---|---|
| Price | $10.16 | $4.97 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $18.88 |
| AVG Volume (30 Days) | 127.7K | ★ 1.4M |
| Earning Date | 01-01-0001 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 165.16 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,998,000.00 |
| Revenue This Year | N/A | $804.33 |
| Revenue Next Year | N/A | $119.68 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 258.18 |
| 52 Week Low | $9.87 | $4.00 |
| 52 Week High | $10.19 | $7.65 |
Technical Indicators
Market Signals| Indicator | APXT | ABEO |
|---|---|---|
| Relative Strength Index (RSI) | 59.23 | 34.65 |
| Support Level | $10.12 | $4.94 |
| Resistance Level | $10.19 | $5.36 |
| Average True Range (ATR) | 0.01 | 0.20 |
| MACD | 0.00 | -0.02 |
| Stochastic Oscillator | 100.00 | 11.88 |
Price Performance
Historical ComparisonAbout APXT Apex Treasury Corporation Class A Ordinary Share
Apex Treasury Corp is a blank check company established for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.
About ABEO Abeona Therapeutics Inc.
Abeona Therapeutics Inc is a commercial-stage biopharmaceutical company. The company is focused on developing cell and gene therapies for life-threatening diseases. The company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The company's development portfolio includes adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need.